Treatment of septic shock with immunotherapy

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 565-580

  Smith, Adrienne L ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BRADYKININ ANTAGONIST; CENTOXIN; COLISTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1 ANTAGONIST; ENDOTOXIN NEUTRALIZING PROTEIN; ESTERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN; IBUPROFEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; NITRIC OXIDE SYNTHASE INHIBITOR; POLYMYXIN B; PROTEIN C; PROTEIN S; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAUROLIDINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG DESIGN; DRUG MECHANISM; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTIC SHOCK;

EID: 0031971536     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Shapiro L, Gelfand JA. Cytokines and sepsis: pathophysiology and therapy. New Horizons 1993;1:13-22.
2. Piper RD, Cook DJ, Bone RC, et al. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996;24:2059-70.
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
4. Glauser MP. The inflammatory cytokines: new developments in the pathophysiology and treatment of septic shock. Drugs 1996;52(suppl 2):9-17.
5. Zivot JB, Hoffman WD. Pathogenic effects of endotoxin. New Horizons 1995;3:267-75.
6. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680-7.
7. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996;24: 163-72.
8. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1992;115:457-69.
9. McCabe WR. Serum complement levels in bacteremia due to gram-negative organisms. N Engl J Med 1973;288:21-3.
10. Van der Poll T, Buller HR, Ten Cate HT, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;332:1622-7.
11. Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320:1165-72.
12. Bone RC. Why sepsis trials fail [commentary]. JAMA 1996;276:565-6.
13. Stephenson J. Reflecting and regrouping after failed trials, sepsis researchers forge on [editorial]. JAMA 1996;275:823-4.
14. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
15. Rackow ED, Astiz ME. Pathophysiology and treatment of septic shock. JAMA 1992;266:548-54.
16. Chedid L, Parant M, Parant F, et al. A proposed mechanism for natural immunity to enterobacterial pathogens. J lmmunol 1968;100:292-306.
17. Braude AI, Ziegler EJ, McCutchan JA, et al. Immunization against nosocomial infection. Am J Med 1981;70:463-6.
18. McCabe WR, Greely A. Immunization with R mutants of Salmonella minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 1972;108:601-10.
19. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gramnegative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-30.
20. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992;327:234-40.
21. Calandra T, Glauser MP, Schellekens J, et al. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 1988;158:213-19.
22. Greenman RL, Schein RM, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1992;266:1097-1102.
23. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1005.
24. Ziegler EJ, Fisher CJ, Sprug CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-36.
25. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 1994;121:1-5.
26. Seigel JP, Stein KE, Zoon KC. Anti-endotoxin monoclonal antibodies - FDA editorial response. N Engl J Med 1992;327: 890-1.
27. Cross AL. Antiendotoxin antibodies: a dead end? [editorial]. Ann Intern Med 1994;121:58-60.
28. Cohen J, Heumann D, Glauser MP. Do monoclonal antibodies and anticytokines still have a future in infectious disease? Am J Med 1995;99(suppl 6A):45-53.
29. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
30. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy of mortality in patients with clinical signs of systemic sepsis. N EnglJ Med 1987;317:659-65.
31. Lowry SF. Anticytokine therapies in sepsis. New Horizons 1993;1:120-6.
32. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
33. Pinsky MR, Vincent JL, Deviere J. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565-75.
34. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1992;163:1177-84.
35. Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985;228:1149-54.
36. March CJ, Mosely B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985;315:641-7.
37. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985;229:869-71.
38. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662-4.
39. Opal SM, Cross AS, Kelley NM, et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1990;161:1148-52.
40. Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative septic shock. J Infect Dis 1990;162:421-7.
41. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990;30:279-92.
42. Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg 1992;127:138-45.
43. Fisher CJ, Opal SM, Dhainaut JF, et al. Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-27.
44. Dhainaut JF, Vincent JL, Richard C, et al. CD571, a humanized antibody to human tumor necrosis factor-a: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995;23:1461-9.
45. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733-42.
46. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of a monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995;273:934-41.
47. Cohen J, Cartlet J, for the INTERSEPT Study Group. INTERSEPT: an international, multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996;24:1431-40.
48. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-702.
49. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA 1997;277:1531-8.
50. Ashkenazi A, Marsters SA, Capon DJ. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1992;21:2883-6.
51. Peppel K, Crawford D, Beutler B. Tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1992;174:1483-9.
52. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanism of its multiple actions. J Biol Chem 1991;266:7313-16.
53. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9.
54. Ohlsson K, Bjork P, Bergenfeldt M, et al. An interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
55. Fischer E, Marano MA, VanZee KJ, et al. lnterleukin-1 receptor blockade improves survival and hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-7.
56. Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
57. Fisher CJ, Dhainaut JF, Opal SM. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
58. Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-24.
59. Koltai M, Hosford D, Braquet PG. Platelet-activating factor in septic shock. New Horizons 1993;1:87-95.
60. Dhainaut JF, Tenaillon A, LeTulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22:1720-8.
61. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
62. Cross AS, Opal SM, Sadoff JC, et al. Choice of bacteria in animal models of sepsis. Infect Immunol 1993;61:2741-7.
63. Warren HS, Danner RF, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992;326:1153-7.
64. Nitsche D, Schulze C, Osser S, et al. Impact of different classes of antimicrobial agents on plasma endotoxin activity. Arch Surg 1996;131:192-9.
65. Mock CN, Jurkovich GJ, Dries DJ, et al. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 1995;130:1234-40.
66. Crosby HA, Bion JF, Penn CW, et al. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994;40:23-30.
67. Hillburger ME, Adler MW, Truant AL, et al. Morphine induces sepsis in mice. J Infect Dis 1997;176:183-8.
68. Sibbald WJ, Vincent JL. Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 1995;23:394-9.
69. Eidelman LA, Sprug CL. Why have new effective therapies for sepsis not been developed? Crit Care Med 1994;22:1330-4.
70. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis, with a novel bradykinin antagonist, deltibant (CP-0127). JAMA 1997;277:482-7.
71. Kuhns DB, Alyord G, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995;171:145-52.
72. Friedman G, Jankowski S, Shahla M, et al. Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med 1996;24:229-33.
73. Marra MN, Wilds CG, Collins MS, et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992;148:532-7.
74. Willatts SM, Radford S, Leitermann M. Effect of the antiendotoxic agent taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med 1995;23:1033-9.
75. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-18.
76. Lanser ME, Mao P, Brown G, et al. Serum-mediated depression of neutrophil chemoluminescence following blunt trauma. Ann Surg 1985;202:111-18.
77. Weiss M, Gross-Weege W, Harms B, et al. Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 1996;8:260-5.
78. Barzilay E, Kessler D, Berlot G, et al. Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 1989;17:634-7.
79. Hoffmann JN, Hartl WH, Deppisch R, et al. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med 1996;22:1360-7.
80. Fagan EE, Singer M. Immunotherapy in the management of sepsis. Postgrad Med J 1995;71:71-8.
81. Christman JW, Holden EP, Blackwell TS. Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 1995;23:955-63.
82. Fourrier F, Jourdain M, Tournois A, et al. Coagulation inhibitor substitution during sepsis. Intensive Care Med 1995;21(suppl 2):264-8.
83. Saladino R, Garcia C, Thompson C, et al. Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis. Circ Shock 1994;42:104-10.
84. Kuppermann N, Nelson DS, Saladino RA. Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats. J Infect Dis 1994;170:630-5.
85. Giroir BP. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 1993;236:780-9.
86. Haziot A, Rong G-W, Bazil V, et al. Recombinant soluble CD14 has been shown to prevent mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995;154:6529-32.
87. Cross AS, Opal SM, Parlardy JE, et al. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993;167:112-18.
88. Opal SM, Cross AS, Jhung JW, et al. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis 1996;173:1415-21.